Poster
AI-engineered AAV Capsid Enables Intravitreal Delivery for the Treatment of Diverse Retinal Degenerations
AI-guided, iterative design–screen–validate capsid engineering (NGS-trained viability and retina-targeting models), followed by in vitro assays (HEK293T transduction, serum transduction-inhibition, heparin competition) and in vivo validation in mouse and cynomolgus monkey models via intravitreal delivery.

Overview
Retinal degenerations, including Leber’s congenital amaurosis type 1 (LCA1) and wet age-related macular degeneration (wAMD), represent leading causes of vision impairment and blindness, driven by a range of factors, including genetic mutations and pathological neovascularization. While adeno-associated viruses (AAVs) have emerged as a promising platform for sustained gene therapy, most AAVs typically require subretinal injections to reach target cells, which carry risks to retinal integrity. To overcome this limitation, we employed an AI-guided approach to AAV capsid engineering and developed AAV2.PN168, a novel AAV2-derived variant. AAV2.PN168 exhibits extensive retinal transduction via intravitreal injection in both non-human primates and mice. Furthermore, AAV2.PN168 demonstrates high therapeutic efficacy in mouse models of both LCA1 and wAMD. These findings suggest that AAV2.PN168 has translational potential in treating various retinal degenerations and other ocular diseases requiring efficient, wide-range retinal delivery of therapeutic agents.
Key Insights
A Cyagen/YIMA Gene conference poster presenting AAV2. PN168, an AI-engineered AAV2 capsid variant that achieves broad retinal transduction via intravitreal injection and shows therapeutic efficacy in mouse models of LCA1 and wet AMD.
- AI-guided capsid engineering worked. NGS-trained models predicted capsid viability and retinal targeting with high accuracy (Spearman R ≈ 0.90 mouse, 0.895 NHP), and an iterative design–screen–validate loop over ~45–49 variants converged on AAV2.PN168.
- Outperforms the current benchmark in both species. In cynomolgus monkeys, PN168 gave significantly higher GFP+ ONL cell ratios than AAV2.7m8 across macula, central, and peripheral retina; in mice it led on luminescence, fundus/section fluorescence, and eGFP mRNA versus AAV2.WT and 7m8.
- Therapeutic proof-of-concept via the safer route. A single intravitreal dose restored ERG b-wave amplitudes in GucyDKO (LCA1) mice at 28 and 56 days, and PN168-anti-VEGFA produced durable recovery of subretinal exudation in hVEGFA-TG (wAMD) mice — suggesting an alternative to subretinal surgery and repeated anti-VEGF injections.
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
